FDA approves 1st treatment for Menkes disease, offering a copper therapy that improves survival in affected children.

Biological heterogeneity in autism can illuminate precision psychiatry and improve insights from primate brain mapping data.

Women’s Health Investment Opportunity reveals a $360B global market as women drive healthcare demand, capital flows, and the next wave of health innovation ...

Explore why tau still lacks treatments despite its critical role in Alzheimer's disease and other tauopathies.

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

Comprehensive format comparison examining capsules, powders, and functional drinks to help consumers evaluate gut health ...

A North Wales police officer who has spent years raising money for others is now fighting for the life of his own son.

The FDA approved copper histidinate (Zycubo) as the first treatment for Menkes disease in pediatric patients, the agency ...

But, under anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has numerous ties to the wellness industry—that FDA ...

Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, ...

Your dermatologist or oncologist may have told you what type of advanced squamous cell carcinoma you have. Here’s what each type means: Locally advanced squamous cell carcinoma: This means cancer has ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...